A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GSK180736A | GSK180736A is a potent and selective inhibitor of GRK2 (IC50 = 0.77 μM) and ROCK1 (IC50 = 14 nM). Synonyms: GSK-180736A; 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide. Grades: >98%. CAS No. 817194-38-0. Molecular formula: C19H16FN5O2. Mole weight: 365.37. |  |
| GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematologic malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo. Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were observed at efficacious doses. GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers. GSK1838705A inhibits ALK, with an IC(50) of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. Synonyms: GSK1838705A; GSK-1838705A; GSK-1838705A. Grades: 0.98. CAS No. 1116235-97-2. Molecular formula: C27H29FN8O3. Mole weight: 532.57. | |
| GSK1842799 | GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosphorylation. It has good oral bioavailability. It was selected as a candidate for further clinical on the basis of the favorable in vitro ADME and in vivo PK/PD properties as well as broad toxicology evaluations. Uses: Gsk1842799 was selected as a candidate for further clinical. Synonyms: (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propan-1-ol;GSK1842799; GSK 1842799; GSK 1842799. Grades: >98 %. CAS No. 1005407-76-0. Molecular formula: C20H28F3N3O2S. Mole weight: 431.52. | |
| GSK-189254 | Cas No. 945493-87-8. | |
| GSK 189254A | GSK-189,254 is a H3 histamine receptor inverse agonist. It has subnanomolar affinity for the H3 receptor with Ki of 0.2nM. It possesses stimulant and nootropic effects and analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. No development was reported about Phase-II clinical trials for Narcolepsy in Europe. Uses: Narcolepsy. Synonyms: 6-((3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-Pyridinecarboxamide. Grades: 98%. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.44. | |
| GSK-189254 free base | GSK-189254 is a potent and selective H3-receptor inverse agonist. It has subnanomolar affinity for the H3 receptor and selectivity of over 10,000x for H3 over other histamine receptor subtypes. Animal studies have shown it to possess not only stimulant and nootropic effects, but also analgesic action suggesting a role for H3 receptors in pain processing in the spinal cord. GSK-189,254 and several other related drugs are currently being investigated as a treatment for Alzheimer's disease and other forms of dementia, as well as possible use in the treatment of conditions such as narcolepsy, or neuropathic pain which do not respond well to conventional analgesic drugs. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK189254; GSK-189254; GSK 189254; GSK-189254 free base. Product Category: Agonists. Appearance: solid powder. CAS No. 720690-73-3. Molecular formula: C21H25N3O2. Mole weight: 351.45. Purity: >98%. IUPACName: 6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy)-N-methylnicotinamide. Canonical SMILES: O=C(NC)C1=CN=C(OC2=CC=C3CCN(C4CCC4)CCC3=C2)C=C1. Product ID: ACM720690733. Alfa Chemistry ISO 9001:2015 Certified. |  |
| GSK-1904529a | GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR-dependent tumors. GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A blocks receptor autophosphorylation and downstream signaling, leading to cell cycle arrest. It inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewing's sarcoma cell lines being most sensitive. Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice, consistent with a reduction of IGF-IR phosphorylation in tumors. Despite the potent inhibitory activity of GSK1904529A on IR in vitro and in vivo, minimal effects on blood glucose levels are observed in animals at doses that show significant antitumor activity. Synonyms: GSK 4529; GSK4529; GSK-4529; GSK1904529a; GSK 1904529; GSK-1904529a. CAS No. 1089283-49-7. Molecular formula: C44H47F2N9O5S. Mole weight: 851.975. | |
| GSK1904529A | GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) , with IC 50 s of 27 and 25 nM, respectively. GSK1904529A shows poor activity ( IC 50 >1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1089283-49-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-10524. |  |
| GSK1997132B | PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. GSK1997132B is a metabolically stable, highly potent centrally penetrant PPARγ partial agonist. Synonyms: GSK 1997132B; GSK-1997132B; GSK1997132B; GSK1997132; GSK-1997132; GSK 1997132. (R)-1-((3,5-difluoropyridin-2-yl)methyl)-2-methyl-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide. Grades: 98%. CAS No. 1168138-37-1. Molecular formula: C24H22F2N4O. Mole weight: 420.46. | |
| GSK199 hydrochloride | GSK199 is a potent and reversible inhibitor of PAD4 with an IC50 value of 200 nM) which is less potent than the related PAD4 inhibitor GSK484 (IC50 = 50 nM). Synonyms: [(3R)-3-amino-1-piperidinyl][2-(1-ethyl-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzimidazol-5-yl]-methanone, monohydrochloride. Grades: ≥98%. CAS No. 1549811-53-1. Molecular formula: C24H28N6O2·HCl. Mole weight: 469. | |
| GSK2018682 | GSK2018682 is an agonist for S1P1 and S1P5 receptor with pEC 50 s of 7.7 and 7.2, respectively, and has no agonist activity towards human S1P2, S1P3, or S1P4. GSK2018682 is used in the research of multiple sclerosis. Uses: Scientific research. Group: Signaling pathways. CAS No. 1034688-30-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-19511. | |
| GSK-2018682 | GSK-2018682 is a potent and selective agonist of sphingosine-1-phosphate receptor (S1PR) subtype 1 that has the potential to treat multiple sclerosis (MS). Synonyms: GSK2018682; GSK 2018682; GSK-2018682. UNII-NJL503AIJA; NJL503AIJA; 4-(4-(5-(5-chloro-6-isopropoxypyridin-3-yl)-1,2,4-oxadiazol-3-yl)-1H-indol-1-yl)butanoic acid. Grades: ≥98%. CAS No. 1034688-30-6. Molecular formula: C22H21ClN4O4. Mole weight: 440.884. | |
| GSK-2033 | GSK-2033 is a potent cell-active LXR antagonist (pIC50 = 7.5). It enhances T-cell proliferation and blocks T 0901317-antiproliferative activity on T-cells and is cell permeable. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK-2033; GSK2033; GSK 2033. Product Category: Antagonists. Appearance: Solid powder. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. Purity: >98%. IUPACName: 2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide. Canonical SMILES: O=S(C1=C(C)C=C(C)C=C1C)(N(CC2=CC=C(C3=CC=CC(S(=O)(C)=O)=C3)C=C2)CC4=CC=C(C(F)(F)F)O4)=O. Product ID: ACM1221277902. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK-2033 | This active molecular is a cell permeable, potent LXR (liver-X-receptor) antagonist. pIC50 values is 7.0 for LXRα and 7.4 for LXR&beta. GSK2033 enhances T-cell proliferation and Th1/Th2/Th17 differentiation when treatment of murine CD41 T cells. Synonyms: GSK-2033; GSK2033; GSK 2033; CHEMBL1093266;GTPL8690; SCHEMBL13280409;2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide. Grades: 98%. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. | |
| GSK2110183 | GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK2110183; GSK 2110183; GSK-2110183. Grades: >98%. CAS No. 1047634-63-8. Molecular formula: C18H16Cl2F2N4OS. Mole weight: 445.31. | |
| GSK2141795 hydrochloride | GSK2141795 Hcl is a potent and selective pan-Akt inhibitor with IC50s of 180/328/38 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK-2141795 Hydrochloride; GSK 2141795 Hydrochloride; GSK2141795 Hydrochloride; GSK2141795 HCl; Uprosertib. Grades: >98%. CAS No. 1047635-80-2. Molecular formula: C18H17Cl3F2N4O2. Mole weight: 465.71. | |
| GSK215083 | GSK215083 is a PET radioligand for the 5-hydroxytrypamine-6 (5HT6) receptor. It is a quinoline based compounds that acts by antagonising the 5-HT6 receptor. It binds to receptors 5HT6 in the striatum and 5-hydroxytryptamine-2A (5HT2A) in the frontal cortex. It is used for the treatment of Alzheimer's disease and used as a PET ligand for identification of occupancy of the 5HT6 receptor coupled with 11C. Uses: Gsk215083 is used for the treatment of alzheimer's disease and used as a pet ligand for identification of occupancy of the 5ht6 receptor coupled with 11c. Synonyms: GSK-215083; GSK 215083; GSK215083; 3-(3-Fluoro-benzenesulfonyl)-8-(4-Methyl-piperazin-1-yl)-quinoline;GSK-215083;Quinoline, 3-((3-fluorophenyl)sulfonyl)-8-(4-methyl-1-piperazinyl)-. Grades: 98%. CAS No. 607742-80-3. Molecular formula: C20H20FN3O2S. Mole weight: 385.46. | |
| GSK2190915 | GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor. It exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. It also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. It increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF). Synonyms: AM-803; AM 803; AM803; 3Fiboflapon; GSK2190915; GSK 2190915; GSK-2190915. Grades: >98%. CAS No. 936350-00-4. Molecular formula: C38H43N3O4S. Mole weight: 637.83. | |
| GSK2190915 sodium salt | GSK2190915(AM-803; Fiboflapon) sodium salt is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM. Synonyms: GSK2190915 sodium salt; GSK 2190915 sodium salt; GSK-2190915 sodium salt; GSK-2190915A; GSK 2190915A; GSK2190915A; Fiboflapon sodium; AM-803 sodium; AM 803 sodium; AM803 sodium. Grades: >98%. CAS No. 1196070-26-4. Molecular formula: C38H42N3NaO4S. Mole weight: 659.81. | |
| GSK2193874 | GSK2193874 is a potent, orally active and specific antagonist of TRPV4 ion channels (IC50 values 2 and 40 nM for rat and human receptors, respectively). GSK2193874 is selective over a panel of ~200 human receptors, channels and enzymes. Synonyms: GSK2193874; GSK 2193874; GSK-2193874; GSK2193874A; GSK 2193874A; GSK-2193874A; 7-bromo-N-(1-phenylcyclopropyl)-3-[(4-piperidin-1-ylpiperidin-1-yl) methyl]-2-[3-(trifluoromethyl)phenyl]quinoline-4-carboxamide. CAS No. 1336960-13-4. Molecular formula: C37H38BrF3N4O. Mole weight: 691.62. | |
| GSK2194069 | GSK2194069 is a fatty acid synthase (FAS) inhibitor. GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ± 4.1 nM for the overall hFAS reaction. FAS is upregulated in some cancers, including prostate cancer. GSK2194069 was found to inhibit tumour growth in prostate cancer C42b cell xenografts generated in Nod-SCID-gamma mice. Cellular FAS inhibition reduced cell growth were also demonstrated in non-small-cell lung (A549) cancer cell lines with an average EC50 of 15 ± 0.5 nM. Synonyms: GSK 2194069; GSK-2194069. Grades: >98%. CAS No. 1332331-08-4. Molecular formula: C25H24N4O3. Mole weight: 428.48. | |
| GSK2245035 | This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of GlaxoSmithKline. GSK2245035 displays potent IFNα inducing potency and IFNα/TNFα selectivity. In Aug 2015, GlaxoSmithKline completed a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada. In Jul 2016, GlaxoSmithKline planed a phase II trial for Allergic asthma in Germany (Intranasal). Uses: Allergic asthma; allergic rhinitis. Synonyms: GSK2245035; GSK 2245035; GSK-2245035; (S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one;1325212-97-2 (maleate salt). Grades: 98%. CAS No. 1207629-49-9. Molecular formula: C20H34N6O2. Mole weight: 390.52. | |
| GSK2245035 | GSK2245035 is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 has pEC 50 s of 9.3 and 6.5 for IFNα and TFN&alpha. GSK2245035 effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 is used for asthma [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1207629-49-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-118250. | |
| GSK 2250665A | GSK 2250665A is an Itk inhibitor (pKi = 9.2) displaying selectivity for Itk over Aurora B kinase and Btk (pIC50 = 6.4 and 6.5, respectively) and a panel of other kinases. GSK 2250665A was shown to inhibit IFNγ production in PBMCs. Synonyms: GSK-2250665A; GSK 2250665A; GSK2250665A; GSK-2250665; GSK 2250665; GSK2250665; trans-4-[[4-[(6-Ethyl-2-benzothiazolyl)amino]-6-(phenylmethyl)-2-pyrimidinyl]amino]cyclohexanol. Grades: ≥97% by HPLC. CAS No. 1246030-96-5. Molecular formula: C26H29N5OS. Mole weight: 459.61. | |
| GSK2256098 | GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Uses: Scientific research. Group: Signaling pathways. CAS No. 1224887-10-8. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100498. | |
| GSK-2256098 | GSK2256098, also known as GTPL7939, is a focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. Synonyms: GSK2256098; GSK 2256098; GSK-2256098; GTPL7939; GTPL-7939; GTP L7939. Grades: 98%. CAS No. 1224887-10-8. Molecular formula: C20H23ClN6O2. Mole weight: 414.89. | |
| GSK-2256098 hydrochloride | GSK-2256098 hydrochloride is a focal adhesion kinase (FAK) inhibitor that exhibits potential antiangiogenic and antineoplastic activities. GSK-2256098 hydrochloride targets FAK to inhibit tumor cell growth by regulating cell adhesion, migration, proliferation, and survival. Uses: Scientific research. Group: Signaling pathways. CAS No. 1416771-10-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-100498A. | |
| GSK2256294A | GSK2256294A, an effective inhibitor of human soluble epoxide hydrolase(sEH), was developed by GSK and still under Phase I trial in Chronic obstructive pulmonary disease. IC50: 27pM. Uses: Gsk2256294a is an effective inhibitor of human soluble epoxide hydrolase(seh). Synonyms: GSK2256294; GSK-2256294; GSK 2256294; GSK2256294A; GSK-2256294A; GSK 2256294A. UNII-L33EX3XR0T; GSK2256294A; L33EX3XR0T; SCHEMBL2677671; GSK 2256294A. Grades: 98%. CAS No. 1142090-23-0. Molecular formula: C21H24F3N7O. Mole weight: 447.46. | |
| GSK-2262167 hydrate | GSK-2262167 is a potent S1P3-sparing and S1P1 agonist and has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate. Grades: ≥98%. CAS No. 1458576-13-0. Molecular formula: C25H28N4O5. Mole weight: 464.51. | |
| GSK-2262167 sodium | This molecular is a potent S1P3-sparing and S1P1 agonist. Meanwhile GSK-2262167 has a potent activity is in a collagen-induced arthritis model as efficacious as fingolimod and shows excellent pharmacokinetic properties preclinically. Uses: Arthritis. Synonyms: GSK-2262167 sodium; GSK 2262167 sodium; GSK2262167 sodium; sodium 3-(6-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-5-methyl-3,4-dihydroisoquinolin-2(1H)-yl)propanoate,1165924-28-6 (free acid); 458576-13-0 (hydrate). Grades: 98%. CAS No. 1165923-54-5. Molecular formula: C25H25N4NaO4. Mole weight: 468.49. | |
| GSK2269557 | GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma. Uses: Gsk2269557 is an effective pi3k inhibitor that could be used as against inflammatory and some autoimmune diseases. Synonyms: CHEMBL2216859; GSK2269557 (free base); GSK2269557; GSK-2269557; GSK 2269557; Nemiralisib; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole. Grades: 95%. CAS No. 1254036-71-9. Molecular formula: C26H28N6O. Mole weight: 440.54. | |
| GSK-2269557 HCl salt | GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms and is active in a animal model of Th2-driven lung inflammation. Treatment for Asthma and Chronic obstructive pulmonary disease(COPD) is in clinical trials Phase II. Uses: Asthma; chronic obstructive pulmonary disease. Synonyms: GSK-2269557 HCl salt; GSK 2269557 HCl salt; GSK2269557 HCl salt; 6-(1H-indol-4-yl)?-4-[5-[[4-(1-methylethyl)?-1-piperazinyl]?methyl]?-2-oxazolyl]?-1H-indazole, monohydrochloride;1254036-71-9(free base). Grades: 98%. CAS No. 1254036-77-5. Molecular formula: C26H28N6O HCl. Mole weight: 477.01. | |
| GSK2292767 | GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is really active in the animal model of Th2-driven lung inflammation. Uses: Asthma and copd. Synonyms: GSK2292767; GSK-2292767; GSK 2292767. N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethylmorpholin-4-yl]methyl]-1, 3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; SCHEMBL173490; ZINC95938263; KB-78330; 1254036-66-2; Methanesulfonamide, N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]. Grades: 98%. CAS No. 1254036-66-2. Molecular formula: C24H28N6O5S. Mole weight: 512.58. | |
| GSK2330672 | GSK-2330672, an ASBT inhibitor, has been developed for the treatment of type 2 diabetes and is currently under Phase II trail against primary biliary cirrhosis and type 2 diabetes. IC50: 42 ± 3 nM. Uses: Gsk-2330672 is an asbt inhibitor that has been developed for the treatment of type 2 diabetes and is currently under phase ii trail against primary biliary cirrhosis and type 2 diabetes. Synonyms: CHEMBL2387408; UNII-386012Z45S; GSK2330672; GSK-2330672; SCHEMBL2586025; CZGVOBIGEBDYTP-VSGBNLITSA-N. Grades: 98%. CAS No. 1345982-69-5. Molecular formula: C28H38N2O7S. Mole weight: 546.68. | |
| GSK2334470 | GSK2334470 is a potent 3-phosphoinositide-dependent protein kinase (PDK1) inhibitor (IC50 ~ 10 nM), which does not suppress the activity of 93 other protein kinases including 13 AGC-kinases most related to PDK1 at 500-fold higher concentrations. GSK2334470 also inhibited T-loop phosphorylation and activation of Akt. GSK2334470 will be a useful tool for delineating the roles of PDK1 in biological processes. Synonyms: GSK2334470; GSK2334470; GSK2334470. Grades: 0.98. CAS No. 1227911-45-6. Molecular formula: C25H34N8O. Mole weight: 462.602. | |
| GSK239512 | GSK239512 is a potent and brain penetrated H 3 receptor antagonist. GSK239512 can be used for the research of mild-to-moderate Alzheimer's disease (AD) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 720691-69-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-106000. | |
| GSK-239512 | GSK-239512 is a histamine H3 receptor antagonist. In Jun 2015, Phase-II for Schizophrenia in USA was discontinued. Phase II clinical trilas for the treatment of Multiple sclerosis are on-going. Uses: Multiple sclerosis. Synonyms: GSK-239512; GSK239512; GSK 239512; 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-2-Pyrrolidinone. Grades: 98%. CAS No. 720691-69-0. Molecular formula: C23H27N3O2. Mole weight: 377.48. | |
| GSK256066 | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK256066; GSK 256066; GSK-256066. Grades: >98%. CAS No. 801312-28-7. Molecular formula: C27H26N4O5S. Mole weight: 518.58. | |
| GSK256066 2,2,2-trifluoroacetic acid | GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selectivity against PDE4B versus PDE7. Synonyms: GSK-256066; GSK 256066. Grades: >98%. CAS No. 1415560-64-3. Molecular formula: C29H27F3N4O7S. Mole weight: 632.61. | |
| GSK256073 | GSK256073 Inhibitor. Uses: Scientific use. Product Category: T15432. CAS No. 862892-90-8. |  |
| GSK256471 | This active molecular is a selective and potent NK(3) antagonist. It has a high affinity for recombinant human (pK(I) value 8.9) and native guinea pig (pK(I) value 8.4) tachykinin NK(3) receptors. In the near future, GSK256471 may be potentially very useful in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK256471; GSK-256471; GSK 256471. N-[ (S)-cyclopropyl (phenyl)methyl]-3-[[methyl (methylsulfonyl)amino]methyl]-2-phenylquinoline-4-carboxamide. Grades: 98%. CAS No. 1133706-08-7. Molecular formula: C29H29N3O3S. Mole weight: 499.63. | |
| GSK2578215A | Potent leucine-rich repeat kinase 2 (LRRK2) inhibitor (IC50 values are 8.9 and 10.1nm respectively for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 against a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant. Group: Biochemicals. Alternative Names: 5-(2-Fluoro-4-pyridinyl)-2-(phenylm ethoxy)-N-3-pyridinylbenzamide. Grades: Highly Purified. CAS No. 1285515-21-0. Pack Sizes: 10mg, 25mg. US Biological Life Sciences. |  Worldwide |
| GSK2578215A | GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 cells. Synonyms: GSK2578215A; GSK-2578215A; GSK 2578215A. Grades: >98%. CAS No. 1285515-21-0. Molecular formula: C24H18FN3O2. Mole weight: 399.42. | |
| GSK2578215A | GSK2578215A is a potent and highly selective LRRK2 inhibitor, which exhibits IC 50 s of around 10 nM against both wild-type LRRK2 and the G2019S mutant. Uses: Scientific research. Group: Signaling pathways. CAS No. 1285515-21-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13237. | |
| GSK2578999A | GSK2578999A is a potent HIV-1 maturation inhibitor with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. Synonyms: GSK-8999; (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide. CAS No. 1422355-59-6. Molecular formula: C46H62ClNO7. Mole weight: 776.4. | |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Synonyms: GSK2606414; GSK-2606414; GSK 2606414; GSK PERK Inhibitor. 1-(5-(4-Amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone. Grades: 98%. CAS No. 1337531-36-8. Molecular formula: C24H20F3N5O. Mole weight: 451.453. | |
| GSK 2606414 | GSK 2606414. Group: Biochemicals. Alternative Names: 7-Methyl-5-[1-[[3- (trifluoromethyl) phenyl]acetyl]-2, 3-dihydro-1H-indol-5-yl]-7H-pyrrolo[2, 3-d]pyrimidin-4-amine. Grades: Highly Purified. CAS No. 1337531-36-8. Pack Sizes: 1mg. Molecular Formula: C24H22F3N5O, Molecular Weight: 453.46. US Biological Life Sciences. | Worldwide |
| GSK2636771 | GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Uses: Antineoplastic agents. Synonyms: GSK2636771; GSK-2636771; GSK 2636771. CAS No. 1372540-25-4. Molecular formula: C22H22F3N3O3. Mole weight: 433.431. | |
| GSK2636771 | GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3Kβ with a K i of 0.89 nM and an IC 50 of 5.2 nM, showing 900-fold selectivity over p110α and p110γ, and 10-fold selectivity over p110δ isoforms. Uses: Scientific research. Group: Signaling pathways. CAS No. 1372540-25-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15245. | |
| GSK 264220A | GSK 264220A is an endothelial lipase and lipoprotein lipase inhibitor (IC50 = 0.13 and 0.10 μM, respectively). Inhibition of endothelial lipase may lead to an increase in HDL levels and GSK 264220A is expected to be a therapy for cardiovascular disease. Uses: Potential treatment of cardiovascular disease. Synonyms: GSK-264220A; GSK 264220A; GSK264220A. N-[2-Methyl-5-(1-piperidinylsulfonyl)-3-furanyl]-N'-phenylurea; 3-[2-methyl-5-(piperidine-1-sulfonyl)furan-3-yl]-1-phenylurea; 1-(2-methyl-5-piperidin-1-ylsulfonylfuran-3-yl)-3-phenylurea. Grades: ≥98% by HPLC. CAS No. 685506-42-7. Molecular formula: C17H21N3O4S. Mole weight: 363.43. | |
| GSK 264220A | GSK 264220A. Group: Biochemicals. Grades: Purified. CAS No. 685506-42-7. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK2656157 | GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC50 of 0.9 nM. It is highly selective for PERK with IC50 values >100 nM against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC50 in the range of 10-30 nM as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CHOP proteins in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK auto-phosphorylation. Twice daily dosing of GSK2656157 results in dose dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density and vascular perfusion are potential mechanisms for the observed anti-tumor effect. However, despite its anti-tumor activity, given the on-target pharmacological effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients. Synonyms: GSK2656157; GSK 2656157; GSK-2656157. Grades: 0.98. CAS No. 1337532-29-2. Molecular formula: C23H21FN6O. Mole weight: 416.46. | |
| GSK 269962 | GSK 269962 is a potent ROCK inhibitor with IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively, which displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. It may be used in OAB treatment. It has been shown to block the generation of inflammatory cytokines in lipopolysaccharide-stimulated monocytes and to induce vasorelaxation in preconstricted rat aorta (IC50 = 35 nM). It lowers blood pressure in a rat model of hypertension. It induced a reduction in blood pressure of approximately 10, 20, and 50 mm Hg at doses of 1, 3, and 30 mg/kg. It represent a novel class of ROCK inhibitors that have profound effects in the vasculature, which may enable us to further evaluate the potential beneficial effects of ROCK inhibition in animal models of cardiovascular as well as other chronic diseases. Uses: Gsk 269962 may be used in oab treatment. it represent a novel class of rock inhibitors. Synonyms: GSK269962A; N-[3-[[2-(4-Aminofurazan-3-yl)-1-ethyl-1H-imidazo[4, 5-c]pyridin-6-yl]oxy]phenyl]-4-[[2-(4-morpholinyl)ethyl]oxy]benzamide; Aminofurazanyl-azabenzimidazole 6n;N-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide. Grades: >99 %. CAS No. 850664-21-0. Molecular formula: C29H30N8O5. Mole weight: 570.60. | |
| GSK269962A HCl | GSK269962 is a selective inhibitor of ROCK (Rho-associated protein kinase) with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. GSK269962 displays > 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Synonyms: GSK269962B; GSK269962; GSK 269962. Molecular formula: C29H30N8O5·HCl. Mole weight: 607.06. | |
| GSK-270822A | GSK-270822A is a G protein-coupled receptor kinases(GRK2) inhibitor, which has been directly implicated in the progression of heart failure. It would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to Parkinson's disease. Uses: Gsk-270822a would be used as useful chemical probes and leads for therapeutic applications ranging from heart failure to parkinson's disease. Synonyms: GSK270822A; GSK 270822A; N-(1H-indazol-5-yl)-2-methyl-4-(naphthalen-2-yl)-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxamide; NSC-756163. Grades: 98%. CAS No. 864082-23-5. Molecular formula: C24H20N4O2. Mole weight: 396.45. | |
| GSK2801 | GSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins.probes/GSK2801). Synonyms: GSK2801; GSK-2801; GSK 2801. Grades: 98%. CAS No. 1619994-68-1. Molecular formula: C20H21NO4S. Mole weight: 371.45. | |
| GSK2807 Trifluoroacetate | GSK2807 Trifluoroacetate is a potent, selective and SAM-competitive inhibitor of SMYD3 , with a K i of 14 nM and an IC 50 of 130 nM [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2245255-66-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-104009A. | |
| GSK-2818713 | GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex inhibitor, GSK-2818713 exhibited picomolar potency on genotype 1 variants. Uses: The treatment of hepatitis c. Synonyms: GSK-2818713; GSK2818713; GSK 2818713. | |
| GSK2830371 | GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM. Synonyms: GSK 2830371; GSK2830371; GSK-2830371. Grades: >98%. CAS No. 1404456-53-6. Molecular formula: C23H29ClN4O2S. Mole weight: 461.02. | |
| GSK2837808A | GSK2837808A is a potent and specific lactate dehydrogenase A (LDHA) with IC50 values of 1.9 and 14 nM for LDHA and LDHB, respectively and inhibits lactate production in selected cancer cell lines. Synonyms: GSK2837808A; GSK-2837808A; GSK 2837808A; GSK2837808; GSK-2837808; GSK 2837808. 3-[[3-(cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl]amino]-5-(3,5-difluorophenoxy)benzoic acid. CAS No. 1445879-21-9. Molecular formula: C31H25F2N5O7S. Mole weight: 649.62. | |
| GSK2838232 | GSK2838232, a derivative of Betulin, is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. Uses: Anti-hiv agents. Synonyms: GSK2838232; GSK-2838232; GSK 2838232; 4-[[(3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo-1-propan-2-yl-4, 5, 6, 7, 7a, 9, 10, 11, 11b, 12, 13, 13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2, 2-dime. Grades: 99.34%. CAS No. 1443460-91-0. Molecular formula: C48H73ClN2O6. Mole weight: 809.56. | |
| GSK2879552 | GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes. Uses: Gsk2879552 has been found to be a lsd1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. Synonyms: GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4- ( (4- ( ( ( (1R, 2S) -2-Phenylcyclopropyl) amino) methyl) piperidin-1-yl) methyl) benzoic acid. Grades: 98%. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. | |
| GSK2879552 | GSK2879552 is an orally available, irreversible, inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity. Upon administration, GSK2879552 binds to and inhibits LSD1, a demethylase that suppresses the expression of target genes by converting the dimethylated form of lysine at position 4 of histone H3 (H3K4) to mono- and unmethylated H3K4. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumor-suppressor genes. This may lead to an inhibition of cell growth in LSD1-overexpressing tumor cells. LSD1, overexpressed in certain tumor cells, plays a key role in tumor cell growth and survival. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2879552; GSK-2879552; GSK 2879552. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. Purity: >98%. IUPACName: 4-((4-((((1R,2S)-2-phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid. Canonical SMILES: O=C(O)C1=CC=C(CN2CCC(CN[C@H]3[C@H](C4=CC=CC=C4)C3)CC2)C=C1. Product ID: ACM1401966695. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK2879552 dihydrochloride | GSK2879552 dihydrochloride, a selective, irreversible and orally active lysine specific demethylase 1 (LSD1/KDM1A) inhibitor, has potential antineoplastic activity. Synonyms: Benzoic acid, 4-[[4-[[[(1R,2S)-2-phenylcyclopropyl]amino]methyl]-1-piperidinyl]methyl]-, hydrochloride (1:2); 4-{[4-({[(1R,2S)-2-Phenylcyclopropyl]amino}methyl)-1-piperidinyl]methyl}benzoic acid dihydrochloride. Grades: ≥95%. CAS No. 1902123-72-1. Molecular formula: C23H30Cl2N2O2. Mole weight: 437.40. | |
| GSK-2881078 | GSK-2881078, an indole derivative, has been found to be an androgen receptor modulator that could probably be effective against Cachexia. It is still under Phase I trail. Uses: Anabolic agents. Synonyms: GSK 2881078; GSK2881078; CS-5736; (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)-1H-indole-5-carbonitrile. Grades: 98%. CAS No. 1539314-06-1. Molecular formula: C14H13F3N2O2S. Mole weight: 330.33. | |
| GSK2982772 | GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. Synonyms: GSK2982772; GSK 2982772; GSK-2982772; 5-benzyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1H-1,2,4-triazole-3-carboxamide. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. | |
| GSK2982772 | GSK2982772 is a potent and selective receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate for the Treatment of Inflammatory Diseases. GSK2982772 is, currently in phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis. GSK2982772 potently binds to RIP1 with exquisite kinase specificity and has excellent activity in blocking many TNF-dependent cellular responses. RIP1 has emerged as an important upstream kinase that has been shown to regulate inflammation through both scaffolding and kinase specific functions. Uses: Designed for use in research and industrial production. Additional or Alternative Names: GSK2982772; GSK-2982772; GSK 2982772. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1622848-92-3. Molecular formula: C20H19N5O3. Mole weight: 377.4. Purity: >98%. IUPACName: (S)-5-Benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b]-[1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide. Canonical SMILES: O=C(C1=NN=C(CC2=CC=CC=C2)N1)N[C@@H]3C(N(C)C4=CC=CC=C4OC3)=O. Product ID: ACM1622848923. Alfa Chemistry ISO 9001:2015 Certified. | |
| GSK299115A | GSK299115A is a G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor. Synonyms: GSK299115A; GSK 299115A; GSK-299115A. 4-(3,4-dichlorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyridine-5-carboxamide. Grades: 98%. CAS No. 864082-35-9. Molecular formula: C20H16Cl2N4O2. Mole weight: 415.27. | |
| GSK299423 | GSK299423 is an antibiotic agent and it seems potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. GSK299423 is a Type II bacterial DNA topoisomerase inhibitor under the development of GlaxoSmithKline. Early research for the treatment of Gram-negative infections and Nosocomial infections was on-going in USA. Uses: Gram-negative infections; nosocomial infections. Synonyms: GSK299423; GSK 299423; GSK-299423; 4-(2-(4-(([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino)piperidin-1-yl)ethyl)-6-methoxyquinoline-3-carbonitrile. Grades: 98%. CAS No. 1352149-24-6. Molecular formula: C25H27N5O2S. Mole weight: 461.58. | |
| GSK3004774 | GSK3004774 is a potent, nonabsorbable agonist of CaSR , with an pEC 50 of 7.3, 6.6 and 6.5 for human, mouse and rat CaSR, respectively. GSK3004774 shows an EC 50 of 50 nM for human CaSR [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2138814-32-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-107773. | |
Our database is helping our users find suppliers everyday.
